Document is current
Any future updates will be listed below
-
Authors
Patterson, S. D.
Gottschalk, A.
Hayden, C.
Young, R.
Hair, A.
Jørgensen, H. G. https://orcid.org/0000-0003-4663-4191
Wheadon, H. W. https://orcid.org/0000-0001-9902-3170
Apperley, J. F. https://orcid.org/0000-0002-1710-1794
Glauche, I. https://orcid.org/0000-0002-2524-1199
Clark, R. E.
Copland, M. https://orcid.org/0000-0002-7655-016X
Roeder, I. https://orcid.org/0000-0002-6741-0608
-
Funding
Funding for this research was provided by:
Cancer Research UK (CRCPJT/100006)
Cancer Research UK (CRCPJT/100006)
Cancer Research UK (CRCPJT/100006)
Bloodwise (11017)
Bloodwise (13020)
- License Information
-
More Information
Article History
Received: 22 August 2025
Revised: 19 November 2025
Accepted: 12 December 2025
First Online: 7 January 2026
Competing interests
: M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Ascentage, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer, Janssen and Jazz Pharmaceuticals. J.F.A has received research funding from Incyte and Pfizer, is/has been an advisory board member for Ascentage, Incyte, Novartis and Terns, and has received honoraria from Incyte and Novartis. The remaining authors have no disclosures.
: This study was conducted in alignment with the Declaration of Helsinki and under the DESTINY clinical trial ethics approval from the NRES Committee North West and Liverpool East (13/NW/0265), and the Hematological Cell Research Bank Research (Tissue Bank Approval) from the West of Scotland REC 4 (20/WS/0066). Written informed consent was obtained from DESTINY trial participants prior to sample acquisition for the use of their samples in this study. All methods used in this study were performed in accordance with the relevant local institutional and national guidelines.
